Open Access
- 5 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 280 (6) , e17-e25
Abstract
Objective: To examine the characteristics of patients with pancreatic cancer with long-term survival. Background: Although pancreatic cancer is a highly lethal malignancy, a minority of patients experience long-term survival. The characteristics of these patients remain largely unidentified. Methods: An indolent subgroup was established using carbohydrate antigen 19-9 (CA19-9), which is the best-validated biomarker for pancreatic cancer. Of 1558 patients, 13.9% were included in the CA19-9–normal (≤37 U/mL) subgroup. Results: A normal CA19-9 level was an independent variable for overall survival (median survival, 18.1 vs 9.7 months, hazard ratio = 0.53, P < 0.001). The 5-year survival of patients with stage IV CA19-9–normal cancer was higher than that of patients with stage I-IV CA19-9-high cancer (22.4% vs 6.8%, P = 0.034). The CA19-9–normal subgroup exhibited reduced levels of circulating glucose (P < 0.001) and increased expression of insulin (P < 0.001) compared with the CA19-9-high subgroup. Glucose was a substrate for CA19-9 biosynthesis through the hexosamine biosynthesis pathway. In addition, in pancreatic cancer animal models of diabetes, glucose control decreased CA19-9 levels and improved overall survival. In a clinical trial (NCT05306028) of patients before undergoing major anticancer treatments, glucose control decreased CA19-9 levels in 90.9% of the patients. Conclusions: CA19-9–normal pancreatic cancer is a strikingly indolent subgroup with low glucose and high insulin. Glucose control is a promising therapeutic strategy for pancreatic cancer.Keywords
This publication has 32 references indexed in Scilit:
- Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort studyBreast Cancer Research and Treatment, 2013
- Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patientsLung Cancer, 2012
- Serum CA19-9 Level Associated with Metabolic Control and Pancreatic Beta Cell Function in Diabetic PatientsExperimental Diabetes Research, 2012
- High Glucose Promotes Pancreatic Cancer Cell Proliferation via the Induction of EGF Expression and Transactivation of EGFRPLOS ONE, 2011
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Diabetes and Pancreatic CancerPancreas, 2011
- Diabetes and Cancer: A Consensus ReportCA: A Cancer Journal for Clinicians, 2010
- Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes MellitusGastroenterology, 2008
- Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studiesBritish Journal of Cancer, 2005
- Elevated serum CA19-9 levels in poorly controlled diabetic patients.Japanese Journal of Medicine, 1986